14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates

Antimicrobial Stewardship Core Elements and Regulatory Mandates

Antimicrobial stewardship programs (ASPs) are coordinated, multidisciplinary health-system initiatives designed to optimize clinical outcomes related to antimicrobial use while minimizing unintended consequences, including toxicity, healthcare expenditures, and the emergence of antimicrobial resistance. Driven by escalating resistance threats and landmark epidemiological data demonstrating that 30% to 50% of inpatient antibiotic prescriptions are inappropriate or unnecessary, antimicrobial stewardship has evolved from an institutional quality recommendation into a strictly enforced regulatory and accreditation mandate.

---

Foundational Rationale and Clinical Objectives

The Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), and Pediatric Infectious Diseases Society (PIDS) establish that the primary goal of antimicrobial stewardship is to optimize clinical outcomes while minimizing the unintended consequences of antimicrobial use (toxicity, selection of pathogenic organisms such as Clostridioides difficile, and emergence of resistance). Cost containment is an important secondary benefit but must never supersede patient safety and clinical efficacy.

                    THE DUAL MANDATE OF ANTIMICROBIAL STEWARDSHIP

     OPTIMIZE CLINICAL OUTCOMES                       MITIGATE UNINTENDED CONSEQUENCES
  ┌──────────────────────────────────────┐         ┌──────────────────────────────────────┐
  │ • Timely initiation of active agents │         │ • Selection of resistant pathogens   │
  │ • Pathogen-directed de-escalation    │  ◄───►  │ • Hospital-onset C. difficile (HO-CDI)│
  │ • Precision PK/PD dose optimization  │         │ • Organ toxicities (AKI, DILI, etc.) │
  │ • Evidence-based short durations     │         │ • Preventable drug expenditures      │
  └──────────────────────────────────────┘         └──────────────────────────────────────┘

---

The CDC Core Elements of Hospital Antibiotic Stewardship Programs

First published in 2014 and comprehensively updated in 2019, the Centers for Disease Control and Prevention (CDC) 7 Core Elements of Hospital Antibiotic Stewardship Programs define the baseline structural and functional components necessary for an effective ASP across acute care hospitals:

1. Hospital Leadership Commitment

Dedication of necessary financial, human, and information technology resources to ensure program viability. Meaningful leadership support requires:

• Protected Time and Salary Support: Allocating dedicated, non-clinical operational full-time equivalents (FTE) for the stewardship physician and pharmacist leaders, commensurate with facility bed size and acuity.
• Information Technology Resources: Providing electronic health record (EHR) tools, computerized clinical decision support systems (CDSS), and automated data extraction for national registry reporting.
• Direct Governance Reporting: Establishing regular, formal reporting lines from the ASP to the hospital Board of Directors, Medical Executive Committee, and Quality/Patient Safety Committees.

2. Accountability

Designation of a single physician leader responsible for overall program outcomes.

• The physician director should ideally possess formal training in Infectious Diseases (ID fellowship) or documented clinical expertise in antimicrobial stewardship.
• In smaller or critical access hospitals where an on-site infectious diseases physician is unavailable, a hospitalist or intensivist co-lead supported by formal tele-stewardship consultation satisfies this requirement.

3. Pharmacy Expertise (Formerly "Drug Expertise")

Designation of a single pharmacist leader responsible for coordinating stewardship interventions.

• The designated pharmacist should ideally have specialized post-graduate training (PGY2 Infectious Diseases residency), Board Certification in Infectious Diseases Pharmacotherapy (BCIDP), or completed recognized certificate training (e.g., SIDP/MAD-ID stewardship certificates).
• A co-leadership structure pairing the physician leader and the clinical pharmacy specialist represents the gold standard operational model.

4. Action

Implementation of evidence-based interventions to improve antibiotic use. The CDC stratifies actions into priority categories:

• Priority Core Interventions:
  • Prospective Audit and Feedback (PAF): Review of antibiotic orders by an ASP pharmacist or physician at 24 to 72 hours post-prescription with direct, collegial recommendations.
  • Preauthorization (Formulary Restriction): Requiring stewardship approval prior to dispensing designated broad-spectrum or high-cost antimicrobials.
  • Facility-Specific Clinical Guidelines: Developing locally tailored, antibiogram-informed management pathways for common inpatient syndromes (community-acquired pneumonia, hospital-acquired pneumonia, complicated urinary tract infections, skin and soft tissue infections, and intra-abdominal sepsis).
• Pharmacy-Driven Process Interventions:
  • Automatic intravenous-to-oral (IV-to-PO) conversion protocols for drugs with high oral bioavailability (fluoroquinolones, linezolid, metronidazole, fluconazole, trimethoprim-sulfamethoxazole, doxycycline).
  • Pharmacokinetic dosing services (precision aminoglycoside and vancomycin AUC monitoring).
  • Dose adjustment for organ dysfunction (renal/hepatic dosing protocols).
  • Automatic stop orders for time-limited empiric therapy (e.g., surgical prophylaxis discontinued within 24 hours postoperatively).
  • Duplicate spectrum redundancy alerts (e.g., preventing simultaneous anaerobic coverage with piperacillin-tazobactam plus metronidazole).
• Diagnostic and Diagnostic Stewardship Interventions:
  • Rapid diagnostic testing (RDT) on positive blood cultures paired with real-time active ASP notification.
  • Reflex urine culture algorithms and respiratory viral panel stewardship to prevent unnecessary antibiotic initiation for colonization or viral syndromes.

5. Tracking

Continuous monitoring of antibiotic prescribing patterns, process measures, and patient outcomes:

• Consumption Metrics: Quantifying usage using Days of Therapy (DOT) or Defined Daily Dose (DDD), normalized to patient census (e.g., per 1,000 patient days or days present).
• Benchmark Reporting: Submitting data to the CDC National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) Option to track the Standardized Antimicrobial Administration Ratio (SAAR).
• Process Measures: Documenting acceptance rates of stewardship recommendations, time to de-escalation, guideline adherence, and blood culture contamination rates.
• Clinical and Safety Outcomes: Tracking hospital-onset C. difficile infection (HO-CDI) rates, 30-day all-cause mortality, readmissions, and antibiotic-associated adverse drug events (such as acute kidney injury).

6. Reporting

Consistent, actionable communication of prescribing trends and resistance data to prescribers, nursing staff, clinical leadership, and executive boards.

• Distributing provider-specific or unit-specific feedback reports ("prescriber scorecards").
• Presenting annual antibiograms and longitudinal multidrug-resistant organism (MDRO) infection rates.

7. Education

Providing continuing education regarding optimal prescribing, guideline updates, and resistance trends.

• Multi-modal educational approaches (case-based conferences, bite-sized electronic updates, grand rounds, and real-time bedside teaching during audit and feedback).
• Patient and family education regarding appropriate antibiotic expectations and the risks of collateral microbial damage.

---

Regulatory and Accreditation Mandates

Centers for Medicare & Medicaid Services (CMS) Conditions of Participation

In September 2019, CMS finalized federal regulations (42 CFR §482.42 for acute care hospitals and 42 CFR §485.640 for critical access hospitals) mandating that all hospitals participating in Medicare or Medicaid demonstrate an active, hospital-wide antimicrobial stewardship program as a Condition of Participation (CoP). Key CMS requirements include:

• The program must adhere to nationally recognized guidelines (e.g., CDC Core Elements, IDSA/SHEA guidelines).
• The hospital governing body must officially designate an individual (or individuals) qualified through education, training, or experience to lead the ASP.
• The ASP must demonstrate documented coordination across the entire facility, specifically integrating with Infection Prevention and Control (IPC) and Quality Assessment and Performance Improvement (QAPI) programs.
• Measurable improvements in antibiotic utilization and ongoing surveillance of resistance and adverse events must be documented and accessible during CMS survey audits.

The Joint Commission (TJC) Antimicrobial Stewardship Standards

The Joint Commission promulgated revised, heightened Antimicrobial Stewardship Standards (Standard MM.09.01.01) effective January 2023 for hospitals and critical access hospitals, elevating requirements across 12 distinct Elements of Performance (EPs):

• EP 1 (Leadership Allocation): Hospital leadership allocates dedicated financial and human resources for program operations.
• EP 2 (Multidisciplinary Team): Mandatory inclusion of an infectious diseases physician, clinical pharmacist, infection preventionist, and medical technologist.
• EP 3 (National Guidelines): Implementation of evidence-based clinical practice guidelines for at least the top three common infection syndromes (e.g., CAP, UTI, SSTI).
• EP 4 (Preauthorization / PAF): Adoption of at least one core action: preauthorization or prospective audit and feedback.
• EP 5 (Data Collection and SAAR): Collection and analysis of antibiotic use data, explicitly encouraging participation in the NHSN AU Option.
• EP 6 (Action on Disparities): Identification and remediation of disparities in stewardship interventions and prescribing quality across diverse patient populations.

---

Core Operational Strategies: Prospective Audit and Feedback vs. Preauthorization

The 2016 IDSA/SHEA Stewardship Guidelines recommend two foundational, complementary operational strategies for influencing inpatient antimicrobial prescribing: Prospective Audit and Feedback (PAF) and Preauthorization (Formulary Restriction).

                    STEWARDSHIP INTERVENTION TIMING SPECTRUM

     PREAUTHORIZATION                                PROSPECTIVE AUDIT & FEEDBACK (PAF)
 ◄───────────────────────────┬────────────────────────────────────────────────────────►
       Hour 0 (Pre-Order)    │               Hour 24 – 72 (Post-Prescription)
 • Formulary gatekeeping      │ • Prescriber initiates empiric therapy
 • Requires ASP approval     │ • Culture & susceptibility data mature
 • Prevents inappropriate    │ • ASP reviews clinical trajectory
   initial starts            │ • Peer-to-peer de-escalation / discontinuation

1. Prospective Audit and Feedback (PAF)

• Operational Mechanism: Prescribers initiate empiric antimicrobial therapy without prior restrictions. At 24 to 72 hours post-prescription ("the antibiotic timeout"), an ASP pharmacist or physician reviews the patient's electronic medical record, assesses clinical response, evaluates preliminary microbiology (Gram stain, rapid molecular panels, culture/susceptibility results), and provides direct, peer-to-peer recommendations to modify, de-escalate, switch to oral therapy, or discontinue therapy.
• Key Advantages:
  • Preserves Prescriber Autonomy: Eliminates pre-prescription administrative barriers, preventing delays in critically ill septic patients.
  • Enhanced Educational Value: Provides an ideal venue for collegial, case-specific clinical dialogue, explaining the pharmacodynamic and microbiologic rationale behind recommendations.
  • Broad Scope: Evaluates the entirety of the clinical picture, including dose optimization, duration of therapy, and route of administration.
• Key Limitations:
  • Labor-Intensive: Requires substantial protected clinician time to perform daily chart reviews and communicate with prescribers.
  • Delayed Intervention: Inappropriate therapy is administered for the initial 24 to 48 hours before review occurs.
  • Variable Acceptance: Prescribers can decline recommendations; success depends heavily on institutional culture and interpersonal rapport.

2. Preauthorization (Prior Authorization / Formulary Restriction)

• Operational Mechanism: Specific broad-spectrum, toxic, or high-cost antimicrobials are designated as "restricted" on the hospital formulary (e.g., daptomycin, meropenem-vaborbactam, ceftazidime-avibactam, cefiderocol, echinocandins). To obtain the drug, the bedside clinician must contact the ASP approval team (on-call ID fellow, attending, or clinical pharmacist) and justify clinical criteria prior to the pharmacy dispensing the first dose.
• Key Advantages:
  • Immediate Control: Directly prevents inappropriate initiation of empiric broad-spectrum therapy at hour zero.
  • Rapid Cost Containment: Halts unwarranted utilization of novel, expensive agents, producing immediate drug acquisition cost savings.
  • Direct Expert Consultation: Facilitates early engagement with infectious diseases specialists in complex infections.
• Key Limitations:
  • Risk of Treatment Delays: If authorization processes are cumbersome or off-hours staffing is inadequate, the administration of time-sensitive first doses in septic shock can be dangerously delayed.
  • Prescriber Friction and Fatigue: Often perceived by bedside clinicians as bureaucratic gatekeeping, breeding resentment toward the stewardship team.
  • The "Squeeze the Balloon" Effect (Displacement): Restricting one targeted agent often shifts prescribing pressure toward alternative, unmonitored broad-spectrum agents (e.g., restricting carbapenems may drive excessive, inappropriate piperacillin-tazobactam or cefepime use).

Hybrid Operational Models and Modern Implementation

Contemporary high-functioning ASPs rarely choose between PAF and preauthorization in isolation. Instead, guidelines endorse a hybrid operational framework:

1. Preauthorization for Restricted Novel and High-Risk Agents: Reserving preauthorization for high-consequence antimicrobials, including novel beta-lactam/beta-lactamase inhibitor combinations (ceftolozane-tazobactam, imipenem-cilastatin-relebactam), siderophore cephalosporins (cefiderocol), and reserve antifungals (isavuconazole, liposomal amphotericin B).
2. Prospective Audit and Feedback for High-Volume Backbone Agents: Deploying PAF for high-utilization broad-spectrum agents (vancomycin, piperacillin-tazobactam, cefepime, meropenem, fluoroquinolones) at 48 hours to streamline de-escalation once microbiologic data return.
3. Conditional Preauthorization with "First Dose Free": Mitigating treatment delays by permitting the initial 12 to 24 hours of therapy without prior approval (allowing rapid emergency dispensing), while requiring authorization for continuation beyond 24 hours.
4. Synergistic Clinical Decision Support (CDSS): Leveraging EHR rule engines to flag redundant spectra, renal mismatch, and positive blood culture rapid diagnostic results in real time.